Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Article

    Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: A comparative study

    Rajiv Mahajan1★, Anita Gupta2, Rajinder Singh Gupta3, Kapil Gupta4★ Corresponding author

    1. 1Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 151 109, Punjab.
    2. 2Departments of Pharmacology and, Institute of Medical Sciences and Research, Bathinda - 151 109, Punjab.
    3. 3General Medicine, Government Medical College, Patiala - 147 001, Punjab.
    4. 4Department of Biochemistry, Adesh Institute of Medical Sciences and Research, Bathinda - 151 109, Punjab, India Research Paper.

    CORRESPONDENCE

    Rajiv Mahajan

    Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 151 109, Punjab.

    drrajivmahajan01@yahoo.co.in

    Volume 1, Issue 2 · pp. 82–86 · PUBLISHED 2010 · DOI: 10.4103/0976-500X.72349

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Objectives: Prevalence of metabolic syndrome (MS) is ~25% and it is currently becoming prevalent in children also. India is estimated to have the maximum number of patients of MS in the world. As insulin resistance is an integral part of MS and the rate of secondary sulfonylurea failure (SSUF) is also high, the present study was planned to evaluate the effects of insulin sensitizers as add-on therapy in MS with SSUF. Materials and Methods: An open-label, prospective, randomized study was conducted on 200 patients of MS with SSUF, included according to ATP III criteria, after dividing them into two groups. Group I patients were given pioglitazone 30 mg/day while group II patients were given metformin 1,000 mg/day as add-on therapy to the sulfonylurea already prescribed. Results: Fall in fasting blood glucose, glycosylated hemoglobin and serum triglycerides was higher with metformin, but rise in high-density lipoprotein–cholesterol was higher with pioglitazone. Only metformin caused a significant reduction in body mass index. Significant reduction in waist circumference, systolic blood pressure and diastolic blood pressure was not seen with any therapy. Incremental cost-effective ratio was almost six-times higher with pioglitazone. Conclusion: Among insulin sensitizers, metformin has more favorable, persistent and multifacet effects in MS with SSUF. Studies of longer duration are required for calculating reduction in the mortality and morbidity.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Mahajan, R., Gupta, A., Gupta, R. S., & Gupta, K. (2010). Efficacy, safety and cost-effectiveness of insulin sensitizers as add-on therapy in metabolic syndrome in patients with secondary sulfonylurea failure: A comparative study. Journal of Pharmacology and Pharmacotherapeutics, 1(2), 82–86. https://doi.org/10.4103/0976-500X.72349